- [Joint involvement in chronic inflammatory bowel disease--current diagnostics and treatment options]H Becker
Med Klinik und Poliklinik B, Universitatsklinikum Munster
Z Gastroenterol 44:497-502. 2006..For patients who fail to respond to TNF blockade, the emergence of other targets of the inflammatory cascade may provide more treatment choices in the future...
- Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitidesHeidemarie Becker
Department of Medicine B, University of Muenster, Albert Schweitzer Strasse 33, 48129 Munster, Germany
Clin Rheumatol 25:368-72. 2006..The results suggest that MIF contributes to the inflammatory process and correlates with disease activity in antineutrophil cytoplasmic antibody-associated vasculitides...
- Macrophage migration inhibitory factor may contribute to vasculopathy in systemic sclerosisHeidemarie Becker
Department of Medicine B, University of Muenster, Albert Schweitzer Str 33, 48129, Muenster, Germany
Clin Rheumatol 27:1307-11. 2008..MIF levels were not significantly different in patients with and without macrovascular disease of the peripheral arteries. The results suggest that MIF might contribute to inflammation and vasculopathy in SSc...
- [Leg ulcer in mixed connective tissue disease. Resolution during sitaxsentan therapy]H Becker
Medizinische Klinik und Poliklinik D, Universitatsklinikum Munster, Albert Schweitzer Str 33, 48149 Munster
Z Rheumatol 68:154-6. 2009..In addition, severity of RP ameliorated markedly. Further evaluation of sitaxsentan in patients with connective tissue diseases suffering from ischemic skin ulcers is required...
- Emerging treatment strategies and potential therapeutic targets in primary Sjögren's syndromeHeidemarie Becker
Department of Medicine D, University of Muenster, Muenster, Germany
Inflamm Allergy Drug Targets 9:10-9. 2010..Since efficacy of many agents depends on the presence of residual functional glandular tissue, future studies should focus on patients with recent onset of pSS...
- Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndromePeter Willeke
Department of Medicine B, Muenster University Hospital, Albert Schweitzer Strasse 33, 48129 Muenster, Germany
Arthritis Res Ther 9:R43. 2007..MIF may contribute to B-cell hyperactivity indicated by hypergammaglobulinemia. The inverse relationship of IL-10 and MIF suggests that IL-10 works as an antagonist of MIF in pSS...
- Interferon-gamma is increased in patients with primary Sjogren's syndrome and Raynaud's phenomenonPeter Willeke
Department of Medicine B, Muenster University Hospital, Muenster, Germany
Semin Arthritis Rheum 39:197-202. 2009..Since increased interferon-gamma (INF-gamma) has been associated with RP, we also compared the INF-gamma production in pSS patients with or without RP...
- Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trialPeter Willeke
Department of Medicine B, Muenster University Hospital, Albert Schweitzer Street 33, D 48129 Muenster, Germany
Arthritis Res Ther 9:R115. 2007..Further investigations about the efficacy and safety of MPS in pSS have to be performed in larger numbers of patients...
- Clinical utility of the anti-CCP assay: experiences with 700 patientsUlrich Sauerland
Department of Medicine B, Munster University Hospital, Albert Schweitzer Strasse 33, D 48129 Munster, Germany
Ann N Y Acad Sci 1050:314-8. 2005..Anti-CCP also helps to diagnose other inflammatory and noninflammatory diseases (especially connective tissue diseases) by reducing the rate of false-positive results in comparison with RF...